An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance

被引:7
作者
Micallef, Benjamin [1 ]
Dogne, Jean-Michel [2 ]
Sultana, Janet [3 ]
Straus, Sabine M. J. M. [4 ]
Nistico, Robert [5 ]
Serracino-Inglott, Anthony [1 ,6 ]
Borg, John-Joseph [1 ,5 ]
机构
[1] Med Author, Sir Temi Zammit Bldg,Malta Life Sci Pk, San Gwann SGN 3000, Malta
[2] Univ Namur, Rue Bruxelles 61, B-5000 Namur, Belgium
[3] Univ Exeter, Coll Med & Hlth, Exeter, England
[4] Med Evaluat Board, Utrecht, Netherlands
[5] Univ Tor Vergata, Sch Pharm, Dept Biol, Rome, Italy
[6] Univ Malta, Dept Pharm, Msida, Malta
关键词
ADVERSE DRUG-REACTIONS; DISPROPORTIONALITY ANALYSIS; COMPETITION BIAS; PHARMACOVIGILANCE; SYSTEMS;
D O I
10.1007/s40264-023-01346-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionDuring the signal detection process, statistical methods are used to identify drug-event combinations (DECs) which are disproportionately reported when compared with other drugs and events in the entire database. We hypothesise that the high volume of COVID-19 vaccine adverse drug reaction (ADR) reports transmitted to EudraVigilance may have affected the performance of disproportionality statistics used in routine signal detection, potentially resulting in signals either being masked, or false associations being flagged as potential signals.ObjectiveOur aim was to study the impact of COVID-19 vaccine spontaneous reporting on statistical signal detection in EudraVigilance.MethodsWe recalculated the reporting odds ratio (ROR) for signals that were previously discussed at the level of the Pharmacovigilance Risk Assessment Committee, or signals that were retrieved from EudraVigilance, by omitting COVID-19 vaccine reports from the standard ROR calculation and then comparing the lower confidence interval (LCI) of the recalculated ROR to the LCI of the actual ROR in EudraVigilance.ResultsIn total, 52 signals for 38 active substances were reviewed. For 35 signals, the LCI of the recalculated ROR value was lower than the LCI of the actual ROR (suggesting that COVID-19 vaccine ADR reporting had a positive effect on the strength of the signal) while for 15 signals the LCI of the recalculated ROR value was higher than the LCI of the actual ROR (suggesting that COVID-19 vaccine ADR reporting had an attenuating effect on the strength of the signal). For two signals, no change in the ROR was observed. In our analysis, six significant results were found. Five DECs were found to be masked: bleomycin and immune thrombocytopenia (actual ROR LCI = 0.94, recalculated ROR LCI = 1.02), vortioxetine and heavy menstrual bleeding (actual ROR LCI = 0.3, recalculated ROR LCI = 1.06), caplacizumab and heavy menstrual bleeding (actual ROR LCI = 0.98, recalculated ROR LCI = 3.47), ziprasidone and amenorrhoea (actual ROR LCI = 0.84, recalculated ROR LCI = 1.67), and azacitidine and pericarditis (actual ROR LCI = 0.81, recalculated ROR LCI = 2.01). For the DEC of adalimumab and immune reconstitution inflammatory syndrome, the LCI of the actual ROR value was 1.14 and removing COVID-19 vaccine reporting resulted in an LCI of the recalculated ROR value of 0.94 (below threshold).ConclusionsWe demonstrated five cases of masking and one case of false-positive association due to the influence of COVID-19 vaccine spontaneous reporting on the ROR. This suggests that the high number of adverse drug reaction reports for COVID-19 vaccines in EudraVigilance has the potential to affect routine statistical signal detection activities. The impact of COVID-19 vaccine ADR reports on current signal detection practices requires further evaluation and solutions to tackle masking issues in EudraVigilance may need to be developed.
引用
收藏
页码:1089 / 1103
页数:15
相关论文
共 44 条
[1]   Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value [J].
Arlett, Peter ;
Kjaer, Jesper ;
Broich, Karl ;
Cooke, Emer .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) :21-23
[2]   Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance [J].
Bate, Andrew ;
Hornbuckle, Ken ;
Juhaeri, Juhaeri ;
Motsko, Stephen P. ;
Reynolds, Robert F. .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2019, 10
[3]   OpenVigil FDA - Inspection of US American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications [J].
Boehm, Ruwen ;
von Hehn, Leocadie ;
Herdegen, Thomas ;
Klein, Hans-Joachim ;
Bruhn, Oliver ;
Petri, Holger ;
Hoecker, Jan .
PLOS ONE, 2016, 11 (06)
[4]   Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? A Review of the New EU Legislation on Pharmacovigilance [J].
Borg, John-Joseph ;
Aislaitner, George ;
Pirozynski, Michal ;
Mifsud, Stephen .
DRUG SAFETY, 2011, 34 (03) :187-197
[5]   "It seems impossible that it's been made so quickly": a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome [J].
Brown, Poppy ;
Waite, Felicity ;
Larkin, Michael ;
Lambe, Sinead ;
McShane, Helen ;
Pollard, Andrew J. ;
Freeman, Daniel .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
[6]   Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU [J].
Butler, Dianne ;
Vucic, Katarina ;
Straus, Sabine ;
Cupelli, Amelia ;
Micallef, Benjamin ;
Serracino-Inglott, Anthony ;
Borg, John-Joseph .
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) :815-826
[7]   The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions [J].
Candore, Gianmario ;
Monzon, Sebastian ;
Slattery, Jim ;
Piccolo, Loris ;
Postigo, Rodrigo ;
Xurz, Xavier ;
Strauss, Sabine ;
Arlett, Peter .
DRUG SAFETY, 2022, 45 (01) :83-95
[8]   Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases [J].
Candore, Gianmario ;
Juhlin, Kristina ;
Manlik, Katrin ;
Thakrar, Bharat ;
Quarcoo, Naashika ;
Seabroke, Suzie ;
Wisniewski, Antoni ;
Slattery, Jim .
DRUG SAFETY, 2015, 38 (06) :577-587
[9]   Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency [J].
Durand, Julie ;
Dogne, Jean-Michel ;
Cohet, Catherine ;
Browne, Kate ;
Gordillo-Maranon, Maria ;
Piccolo, Loris ;
Zaccaria, Cosimo ;
Genov, Georgy .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (06) :1223-1234
[10]  
European Commission, 2012, COMM IMPL REG EU 520, VL159, P5